Sustained release matrix tablet of 100 mg losartan potassium
Formulation development and in vitro characterization
DOI:
https://doi.org/10.1590/s2175-97902022e20079Keywords:
Hypertension, Losartan potassium, Sustained-release matrix tablet, HPMC, Affinisol, Formulation developmentAbstract
Sustained release matrix tablets of 100 mg losartan potassium HCl were fabricated with two release retarding polymers namely HPMC K100 M and affinisol by direct compression method. Nine trial formulations were prepared by varying content of these polymers, each from 50 mg to 100 mg; keeping the total weight of the tablet 310 mg. The best formulation was selected based on in vitro drug release profile for 12 hours conducted in Type II dissolution apparatus at 50 rpm and water as dissolution medium. Pre-compression parameters such as bulk density, tap density, Carr’s index and Hausner ratio were evaluated for the selected tablet. The tablets were subjected to thickness, weight variation test, drug content, hardness and friability. Drug release kinetics, surface morphology and accelerated stability study were investigated for that selected formulation. Formulation F4 with the composition of 75 mg HPMC K100M and 100 mg affinisol was selected as the best formulation that extended the drug release up to 12 hours. Pre-compression parameters and other tableting properties were within the Pharmacopoeia limit. Release kinetics analysis proved non-fickian zero-order drug release and that was further confirmed by surface morphology of the tablets before and after dissolution study visualized by SEM. The developed formulation was found to be stable for one month stored at 60 ○C.
Downloads
References
Azharuddin M, Kamath K, Paneerselvan T, Pillai SS, Shabaraya AR. Formulation and evaluation of controlled release matrix tablets of antihypertensive drug using natural and synthetic hydrophilic polymers. Res Biotech. 2011;2(4):26-32.
Gollapudi R, Javvaji H, Tadikonda RR, Arpineni V. Formulation and in vitro evaluation of sustained release matrix tablets of Losartan potassium. Pharmanest. 2011;2(1):31-6.
Gupta MM, Ray B. A review on: sustained release technology. Int J Ther Appl. 2012;8:1-23.
Gupta BM. Self medication behaviour in hypertensive patients in a tertiary care hospital. J Adv Med Dent Scie Res. 2019;7(2):65-7.
Gupta R, Ram CV. Hypertension epidemiology in India: emerging aspects. Curr Opin Cardiol. 2019;34(4):331-41.
Huang S, O’Donnell KP, Keen JM, Rickard MA, McGinity JW, Williams RO. A new extrudable form of hypromellose: AFFINISOL™ HPMC HME. AAPS PharmSciTech. 2016;17(1):106-19.
Indian Pharmacopoeia. Government of India, ministry of health and family welfare. Delhi: Controller of Publications. 1996;2(35):A117-124.
Isha C, Nimrata S, Rana AC, Surbhi G. Oral sustained release drug delivery system: an overview. J Int Res Pharm. 2012;3(5):57-62.
Kim E, Hwang SH, Kim HK, Abdi S, Kim HK. Losartan, an angiotensin II Type 1 receptor antagonist, alleviates mechanical hyperalgesia in a rat model of chemotherapy-induced neuropathic pain by inhibiting inflammatory cytokines in the dorsal root ganglia. Mol Neurobiol. 2019;56(11):7408-19.
Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25-35.
Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther. 1995;58(6):641-49.
Lozano JV, Llisterri JL, Aznar J, Redon J. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transpl. 2001;16(suppl 1):85-9.
Mahmood SE, Ahmad A, Kashyap S. Prevalence and predictors of hypertension among adults of urban Lucknow, India: A community-based study. Heart India. 2019;7(2):43-8.
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28(12):1462-536.
Mandal U, Gowda V, Ghosh A, Selvan S, Solomon S, Pal TK. Formulation and optimization of sustained release matrix tablet of metformin HCl 500 mg using response surface methodology. Yakugaku Zasshi. 2007;127(8):1281-90.
Mandal U, Pal TK. Sustained release of metformin HCl from hydroxy propyl methyl cellulose matrices: Formulation and in vitro evaluation. Asian J Chem. 2008a;20(2):1163-74.
Mandal U, Pal TK. Formulation and in vitro studies of a fixed-dose combination of a bilayer matrix tablet containing metformin HCl as sustained release and glipizide as immediate release. Drug Dev Ind Pharm. 2008b;34(3):305-13.
Michelson EL. Calcium antagonists in cardiology: Update on sustained-release drug delivery systems. Clin Cardiol. 1991;14(12):947-50.
Nadar, SK. Spotlight on hypertension in the Indian subcontinent. J Hum Hypertens. 2019;33(8):559-61.
Nokhodchi A, Raja S, Patel P, Asare-Addo K. The role of oral controlled release matrix tablets in drug delivery systems. BioImpacts. 2012;2(4):175-87.
O’Donnell KP, Grasman N, Shrestha U, Vanchura B. The utility of AFFINISOL™ HPMC in Hot melt extrusion for supersaturation and controlled release of poorly soluble drugs. In AAPS Annual Meeting 2013.
Patel P. Preformulation Studies: An Integral Part of Formulation Design. In Pharmaceutical Formulation Design-Recent Practices. Intech Open. 2019.
Prenissl J, Manne-Goehler J, Jaacks LM, Prabhakaran D, Awasthi A, Bischops AC, et al. Hypertension screening, awareness, treatment, and control in India: A nationally representative cross-sectional study among individuals aged 15 to 49 years. PLoS Med. 2019;16(5):1-18.
Ramakrishnan S, Zachariah G, Gupta K, Rao JS, Mohanan PP, Venugopal K, et al. Prevalence of hypertension among Indian adults: Results from the great India blood pressure survey. Indian Heart J. 2019;71(4):309-13.
Samyuktha M, Vasanth PM, Suresh K, Ramesh T, Ramesh M. Formulation and evaluation of gastroretentive floating tablets of losartan potassium. Int J Biopharm. 2013;4:18-26.
Shanmugam S, Chakrahari R, Sundaramoorthy K, Ayyappan T, Vetrichelvan T. Formulation and evaluation of sustained release matrix tablets of Losartan potassium. Int J Pharm Tech Res. 2011;3(1):526-34.
Sinha S, Ali M, Baboota S, Ahuja A, Kumar A, Ali J. Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir. AAPS PharmSciTech . 2010;11(2):518-27.
Sung KC, Nixon PR, Skoug JW, Ju TR, Gao P, Topp EM, et al. Effect of formulation variables on drug and polymer release from HPMC-based matrix tablets. Int J Pharm . 1996;142(1):53-60.
Tallapaneni Vishnuvardhan Rao GB, Ahmed MG, Joshi V. Development and evaluation of chitosan based oral controlled matrix tablets of losartan potassium. Int J Pharm Investig. 2012;2(3):157-61.
Toto R, Shultz P, Raij L, Mitchell H, Shaw W, Ramjit D, et al. Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Hypertension. 1998;31(2):684-91.
Velmurugan S, Srinivas P. Formulation and in vitro evaluation of losartan potassium mucoadhesive buccal tablets. Asian J Pharm Clin Res. 2013;6(3):125-30.
Zalte HD, Saudagar RB. Review on sustained release matrix tablet. Int J Phar Biol Sci. 2013;3(4):17-29.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
